| Title |
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
|
|---|---|
| Published in |
PLOS ONE, July 2013
|
| DOI | 10.1371/journal.pone.0066308 |
| Pubmed ID | |
| Authors |
Tamara Castillo-Trivino, Dejana Braithwaite, Peter Bacchetti, Emmanuelle Waubant |
| Abstract |
Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 55% |
| Malaysia | 1 | 9% |
| Spain | 1 | 9% |
| Unknown | 3 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 55% |
| Scientists | 4 | 36% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 2% |
| Denmark | 2 | 1% |
| South Africa | 1 | <1% |
| Brazil | 1 | <1% |
| Finland | 1 | <1% |
| Unknown | 189 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 13% |
| Student > Master | 26 | 13% |
| Researcher | 25 | 13% |
| Student > Bachelor | 24 | 12% |
| Other | 18 | 9% |
| Other | 47 | 24% |
| Unknown | 31 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 85 | 43% |
| Agricultural and Biological Sciences | 18 | 9% |
| Biochemistry, Genetics and Molecular Biology | 13 | 7% |
| Neuroscience | 12 | 6% |
| Immunology and Microbiology | 6 | 3% |
| Other | 22 | 11% |
| Unknown | 41 | 21% |